predicting treatment outcome in classical hodgkin lymphoma genomic advances预测治疗效果在经典霍奇金淋巴瘤基因组进步.pdfVIP

Derenzini E and Younes A Genome Medicine 2011, 3:26 /content/3/4/26 R E V I E W Predicting treatment outcome in classical Hodgkin lymphoma: genomic advances 1 2 Enrico Derenzini and Anas Younes* approximately 11% of all lymphomas in western countries Abstract and has a bimodal age distribution, with a first peak in Classical Hodgkin lymphoma is considered a highly young adults and a second peak around 59 years of age curable disease; however, 20% of patients cannot be [1,2]. HL is currently classified as two distinct disease cured with standard rst-line chemotherapy and have entities: nodular lymphocyte-predominant HL (NLPHL) a dismal outcome. Current clinical parameters do not and classical Hodgkin lymphoma (cHL) [2,3]. In fact, allow accurate risk stratication, and personalized these histologic subtypes have different clinical therapies are lacking. In fact, Hodgkin lymphoma (HL) presentations, age distributions, and prognoses. From a is often over- or undertreated because of this lack of biological and clinical point of view, NLPHL is now accurate risk stratication. In recent years, the early viewed as a distinct disease entity that is more similar to detection of chemoresistance by uorodeoxyglucose indolent B-cell non-HL than to cHL [3]. e prognosis positron emission tomography has become the most for patients with NLPHL is usually good, sometimes even important prognostic tool in the management of HL. without treatment [2,4]. A recent study s